Table 1.
Association between SNCG expression and clinicopathologic characteristics of patients with prostate cancer
| |
SNCG |
NO. samples |
P |
||||
|---|---|---|---|---|---|---|---|
| - | + | ++ | +++ | ||||
| Prostatitis tissues |
10 |
0 |
0 |
0 |
10 |
<0.001 |
|
| BPH tissues |
8 |
0 |
2 |
0 |
10 |
<0.001 |
|
| Prostate cancer tissues (androgen-independent) |
5 |
0 |
0 |
0 |
5 |
<0.001 |
|
| Prostate cancer tissues (androgen-dependent) |
48 |
24 |
31 |
19 |
122 |
|
|
| PSA |
<10 |
22(57.9%) |
9(23.7%) |
6(15.8%) |
1(3.6%) |
38 |
0.004 |
| |
≥10 |
26(31.0%) |
15(17.9%) |
25(29.8%) |
18(21.3%) |
84 |
|
| Gleason score |
≤6 |
19(59.3%) |
6(18.8%) |
5(15.6%) |
2(6.3%) |
32 |
0.037 |
| |
≥7 |
29(32.2%) |
18(20.0%) |
26(28.9%) |
17(18.9%) |
90 |
|
| Clinical stage |
≤T2a |
13(52.0%) |
7(28.0%) |
3(12.0%) |
2(8.0%) |
25 |
0.042 |
| |
≥T2b |
35(36.1%) |
17(17.5%) |
28(28.9%) |
17(17.5%) |
97 |
|
| Lymph node invasion |
Negative |
46(42.2%) |
24(22.0%) |
28(25.7%) |
11(10.1%) |
109 |
<0.001 |
| |
positive |
2(15.4%) |
0 |
3(23.1%) |
8(61.5%) |
13 |
|
| AR |
- |
19(44.2%) |
8(18.6%) |
10(23.3%) |
6(13.9%) |
43 |
0.881 |
| + | 29(36.7%) | 16(20.3%) | 21(26.6%) | 13(16.4%) | 79 | ||